What are the different versions of capmatinib cost?

Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells by inhibiting MET phosphorylation triggered by hepatocyte growth factor binding or MET amplification, blocking MET-mediated phosphorylation of downstream signaling proteins.

What are the different versions of capmatinib cost?

According to market research, the specifications and price information of different versions of capmatinib are sorted out as follows:

1. Laos Lucius Pharmaceutical

Available in a standard dose of 200 mg and in a pack of 60 tablets for long-term use. The price is about 2650 yuan / box.

2. Bangladesh Everest Pharmaceutical

The same dose of 200 mg, but in a pack of 56 tablets, may affect the patient's medication frequency or purchase cycle. The price is about 3600 yuan/box.

3. Novartis Rahika brand

Novartis Pharmaceutical's brand, 200mg dose, 60 tablets, this product enjoys Novartis' reputation and quality control standards. The price is higher, about 12,500 yuan/box.

4. Novartis Pharmaceuticals in Switzerland

The original drug manufacturer offers two dose options, 200mg and 150mg, to meet personalized treatment needs. The combination pack is expensive, about 31,250 yuan/box.

What is the dosage of capmatinib?

According to the drug leaflet, the following are the recommended dosages and dosage adjustments for the drug:

1. Recommended dose

For most patients, the recommended starting dose of capmatinib is set at 400 mg and is given orally twice daily to maintain the effective concentration of the drug in the body. The recommended dosage is designed to ensure that the drug will work stably while minimizing unwanted side effects.

2. Dose adjustment

During the course of treatment, if the patient experiences any adverse reactions, the doctor will adjust the dose accordingly according to the specific situation. The goal of dose adjustment is to minimize patient discomfort while maintaining the effectiveness of the treatment.

On the first adjustment, the dose will be reduced to 300 mg twice daily. If the reduced dose still does not alleviate adverse effects, or if the patient develops new symptoms of intolerance, then the dose will be further reduced to 200 mg twice daily.

This is the bottom line for dose reduction, and if even at this lower dose, the patient is still unable to tolerate it, then permanent discontinuation may need to be considered.

[Warm Tips]: The use of capmatinib needs to be carried out under the guidance of a doctor, and patients should pay close attention to the changes in their condition during the medication process and communicate with the doctor in time to ensure the treatment effect.